Affiliations: [a] Laboratory of Biotechnology, Genomic and Bioinformatics, Faculty of Science and Techniques, Tangier, Abdelmalek Essaâdi University, Tetouan, Morocco | [b] Institute of Nursing, Tangier, Morocco
Correspondence:
[*]
Corresponding author: Said Barrijal, Faculty of Sciences & Techniques of Tangier, Old Road of Airport, Km 10, Ziaten, BP: 416, Tangier, Morocco. E-mail: [email protected]
Abstract: This article is a cross-sectional study of 216 women undergoing adjuvant hormone therapy for breast cancer in two oncology centers in northern Morocco. Quality of life (QoL) was assessed using the Functional Assessment of Cancer Therapy (FACT) questionnaire and its endocrine subscale (ES). The relationship between rural–urban status in our sample and QoL was assessed by linear regression analysis using sociodemographic and clinical variables as covariates. Our results show that physical and functional well-being are significantly (p < 0.001) higher in rural areas (24 and 29, respectively) than in urban areas (16 and 19, respectively), while social and emotional well-being are significantly (p < 0.001) higher in urban areas (22 and 21, respectively) than in rural areas (15 and 16, respectively). However, there was no significant difference (p = 0.097) between rural and urban breast cancer survivors regarding endocrine symptom burden. Regarding the effect of sociodemographic and clinical factors on overall HRQOL of breast cancer survivors, hormone type was shown to have a significant effect on overall HRQOL (FACT-ES) of rural and urban breast cancer survivors (𝛽 = +0.849 and 𝛽 = +0.678, respectively). A similar effect was observed for ES (𝛽 = +0.896 and 𝛽 = +0.180, respectively). In contrast, other factors (age, marital status, economic status, menopausal status, type of surgery) did not have a significant effect on HRQOL (FACT-ES) or ES. The study highlighted the need for increased psychosocial supportive care efforts for rural breast cancer survivors to improve their QoL.
Keywords: Urban, rural, quality of life, breast cancer, survivor, hormonal therapy
DOI: 10.3233/BD-230012
Journal: Breast Disease, vol. 42, no. 1, pp. 291-298, 2023
